98%
921
2 minutes
20
Background: Previous research demonstrated that treatment of acute kidney injury (AKI) with the antioxidant S-PPE NP reduced the levels of the oxidative stress-responsive protein Sestrin2 (SESN2), and suggested that kidney injury molecule 1 (KIM-1) could serve as a biomarker for early tubular injury. A comprehensive elucidation of the regulatory effects of S-PPE NP on SESN2 and KIM-1 expression in ischemia-reperfusion injury-AKI (IRI-AKI) could enhance therapeutic approaches for AKI.
Materials And Methods: An human kidney-2 (HK-2) cell hypoxia/reoxygenation (H/R) model and a mouse IRI model were utilized at various time points to assess the expression of SESN2 and KIM-1 and to evaluate the impact of S-PPE NP treatment. The functionality of the SESN2/AMPK/KIM-1 signaling pathway was also confirmed.
Results: Significant upregulation of SESN2 and KIM-1 was observed in both H/R and IRI models, which was attenuated following S-PPE NP treatment. Overexpression of SESN2 resulted in enhanced AMPK phosphorylation and reduced KIM-1 levels, whereas inhibition of AMPK phosphorylation with compound C did not affect SESN2 levels but led to an increase in KIM-1 levels.
Conclusion: SESN2 serves as a protective factor in the initial phase of renal IRI-AKI, facilitating renal repair by promoting AMPK phosphorylation, which subsequently suppresses KIM-1 expression. Moreover, S-PPE NPs effectively mitigate IRI-AKI by directly scavenging reactive oxygen species and reducing SESN2 expression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150639 | PMC |
http://dx.doi.org/10.1080/0886022X.2025.2509802 | DOI Listing |
Nephrol Dial Transplant
September 2025
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: We investigated circulating protein profiles and molecular pathways among various chronic kidney disease (CKD) etiologies to study its underlying molecular heterogeneity.
Methods: We conducted a proteomic biomarker analysis in the DAPA-CKD trial recruiting adults with and without type 2 diabetes with an eGFR of 25 to 75 mL/min/1.73m2 and a UACR of 200 to 5000 mg/g.
Trop Doct
September 2025
Additional Professor, Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Chikungunya virus (CHIKV) typically causes febrile illness and arthralgia. However, severe complications such as encephalitis, rhabdomyolysis, and multiorgan dysfunction are increasingly recognised, particularly during epidemics in endemic regions. We report a case of a 61-year old male presenting with progressive flaccid paraparesis and respiratory failure following febrile illness.
View Article and Find Full Text PDFPediatr Crit Care Med
September 2025
Division of Critical Care Medicine, National Center for Child Health and Development, Tokyo, Japan.
Objectives: To investigate whether the urine output trajectory is associated with dialysis independence in critically ill children with acute kidney injury (AKI).
Design: Retrospective cohort study.
Setting: A PICU in Japan.
Int J Vitam Nutr Res
August 2025
Department of Endocrinology, Affiliated Hospital of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, 210028 Nanjing, Jiangsu, China.
Background: Dietary interventions have exhibited promise in restoring microbial balance in chronic kidney disease. A low-protein calorie-restricted diet can reduce kidney injury in diabetic rodents. However, whether the renoprotective effects of this dietary intervention in murine diabetic kidney disease models are linked to gut microbiota modulation remains to be determined.
View Article and Find Full Text PDFAustralas J Ageing
September 2025
School of Nursing, Hungkuang University, Taichung, Taiwan.
Objective: Although existing evidence suggests a potential link between dementia and adverse outcomes in patients with COVID-19, a definitive relationship is uncertain. This study aimed to evaluate the impact of dementia on in-hospital outcomes of patients in the presence of COVID-19.
Methods: The US Nationwide Inpatient Sample (NIS) was searched for patients 65 years or older hospitalised for COVID-19 in 2020.